PMID- 30916218 OWN - NLM STAT- MEDLINE DCOM- 20190507 LR - 20200225 IS - 1414-431X (Electronic) IS - 0100-879X (Print) IS - 0100-879X (Linking) VI - 52 IP - 3 DP - 2019 Mar 25 TI - Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis. PG - e7927 LID - S0100-879X2019000300607 [pii] LID - 10.1590/1414-431X20187927 [doi] LID - e7927 AB - Tumor necrosis factor-alpha (TNF-alpha) plays an important role in autoimmune diseases. Previous studies have investigated the association of TNF-alpha-238G/A (rs361525) and -308G/A (rs1800629) polymorphisms with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). However, no agreed conclusion had been made. Therefore, this meta-analysis was conducted to assess the associations of TNF-alpha-238G/A and -308G/A polymorphisms with RA and SLE risk. A systematic search was conducted in commonly used databases. Meta-analysis was performed by STATA12.0. A total of 43 studies were included. In the overall population, the TNF-alpha-238A allele was observed to be a protective factor for RA (A vs G: OR=0.75, 95%CI=0.57-0.99, P=0.040) and the TNF-alpha-308A allele was found to be a risk factor for SLE (A vs G: OR=1.78, 95%CI=1.45-2.19, P<0.001). However, no evidence of association was found between TNF-alpha-238 G/A polymorphism and SLE nor between -308G/A and RA. In the subgroup analysis, TNF-alpha-308A allele played a pathogenic role for RA in Latin Americans (A vs G: OR=1.46, 95%CI=1.15-1.84, P=0.002) and for SLE in Latin Americans (A vs G: OR=2.12, 95%CI=1.32-3.41, P=0.002) and Europeans (A vs G: OR=2.03, 95%CI=1.56-2.63, P<0.001), while it played a protective role for RA in Asians (A vs G: OR=0.54, 95%CI=0.32-0.90, P=0.017). No significant association was found between TNF-alpha-308G/A and SLE susceptibility in Africans and Asians. This meta-analysis demonstrated that TNF-alpha-238A was associated with decreased risk of RA rather than SLE, while -308G/A polymorphism was associated with SLE rather than RA. Stratification analysis indicated that different ethnicities would have different risk alleles. FAU - Chen, Lin AU - Chen L AUID- ORCID: 0000-0002-9547-0261 AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China. FAU - Huang, Zhuochun AU - Huang Z AUID- ORCID: 0000-0002-0415-1426 AD - Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. FAU - Liao, Yun AU - Liao Y AUID- ORCID: 0000-0001-6603-7437 AD - Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. FAU - Yang, Bin AU - Yang B AUID- ORCID: 0000-0003-3679-6664 AD - Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Junlong AU - Zhang J AUID- ORCID: 0000-0002-5196-2707 AD - Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. LA - eng PT - Journal Article PT - Meta-Analysis DEP - 20190325 PL - Brazil TA - Braz J Med Biol Res JT - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas JID - 8112917 RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Arthritis, Rheumatoid/*genetics MH - Genetic Association Studies MH - Genetic Predisposition to Disease MH - Humans MH - Lupus Erythematosus, Systemic/*genetics MH - *Polymorphism, Single Nucleotide MH - Risk Factors MH - Tumor Necrosis Factor-alpha/*genetics PMC - PMC6437938 EDAT- 2019/03/28 06:00 MHDA- 2019/05/08 06:00 PMCR- 2019/03/25 CRDT- 2019/03/28 06:00 PHST- 2018/08/03 00:00 [received] PHST- 2018/12/10 00:00 [accepted] PHST- 2019/03/28 06:00 [entrez] PHST- 2019/03/28 06:00 [pubmed] PHST- 2019/05/08 06:00 [medline] PHST- 2019/03/25 00:00 [pmc-release] AID - S0100-879X2019000300607 [pii] AID - 10.1590/1414-431X20187927 [doi] PST - epublish SO - Braz J Med Biol Res. 2019 Mar 25;52(3):e7927. doi: 10.1590/1414-431X20187927.